All lobbying filings

TODD STRATEGY GROUP

TODD STRATEGY GROUP filed a Q3 report for AMGEN INC. on October 19, 2026, reporting $80,000 in lobbying income.

Lobbying for AMGEN INC. · Biotechnology company.

All filings by TODD STRATEGY GROUP · Everything AMGEN INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 5

PAUL EDATTEL

Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
DANIEL M TODD

Previously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Amin Ctr. Medicare & Medicaid
ERIC BERGREN

Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
KATHERINE FLEMING COTTON

Previously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
NICOLAS MAGALLANES

Previously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Medicare/Medicaid

PBM reform.

Health Issues

Cardiovascular disease awareness and treatment. Bone disease awareness and treatment. Implementation of Inflation Reduction Act. Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).

Pharmacy

Drug pricing and patient affordability. Issues related to 340B. Biosimilars reimbursement and regulatory standards. Issues related to Supply Chain. H.R.1672: Maintaining Investments in New Innovation (MINI) Act.

Budget/Appropriations

Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027.

H.R.3160/S.1553: Promoting and Respecting Economically Viable American Innovation (PREVAIL) Act.

Trade (domestic/foreign)

Issues related to tariffs.

Bills named in this filing 6

H.R. 1
One Big Beautiful Bill Act
H.R. 1672
Maintaining Investments in New Innovation Act
S. 2
Secure America Act
H.R. 8800
National Defense Authorization Act for Fiscal Year 2027
H.R. 3160
PREVAIL Act
S. 1553
PREVAIL Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.